中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 1
Jan.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(1): 104-109

Abnormal liver biochemical parameters in pregnancy during the epidemic of coronavirus disease 2019

DOI: 10.12449/JCH240118
  • 1.

    Department of Gastroenterology，Peking University First Hospital，Beijing 100034，China

  • 2.

    Department of Infectious Diseases，Peking University First Hospital，Beijing 100034，China

More Information
  • Corresponding author: LIU Jianxiang， jxiangliu@sohu.com （ORCID： 0000-0003-0196-6459）
  • Received Date: 2023-03-28
  • Accepted Date: 2023-05-05
  • Published Date: 2024-01-23
    Abstract
  •   Objective  To investigate the differences in abnormal liver biochemical parameters in pregnant patients during the epidemic or non-epidemic period of coronavirus disease 2019 （COVID-19）.  Methods  A retrospective analysis was performed for 539 pregnant women who were discharged from Department of Obstetrics， Peking University First Hospital， from October 2017 to March 2022 and had at least one abnormal liver biochemical parameter among alanine aminotransferase （ALT）， aspartate aminotransferase （AST）， gamma-glutamyl transpeptidase （GGT）， total bilirubin （TBil）， and total bile acid. The patients in the epidemic period of COVID-19 and those in the non-epidemic period of COVID-19 were compared in terms of etiology， coagulation parameters， aminotransferases， bile acid， and renal function. The independent samples t-test was used for comparison of continuous data between two groups， and the chi-square test was used for comparison of categorical data between two groups.  Results  Among the patients discharged from Department of Obstetrics during the non-epidemic period of COVID-19， 262 had abnormal liver biochemical parameters， accounting for 1.46%， while 277 patients had abnormal liver biochemical parameters during the epidemic period of COVID-19， accounting for 1.73% among the patients discharged from Department of Obstetrics during the same period of time， and there was a significant difference between these two groups （χ2=3.947， P=0.047）. The etiological analysis of the patients with abnormal liver biochemical parameters during the two periods showed that there was no difference in the proportion of patients with four pregnancy-specific liver diseases （hyperemesis gravidarum， preeclampsia and eclampsia， intrahepatic cholestasis of pregnancy， and acute fatty liver of pregnancy）. As for the patients with abnormal liver biochemical parameters in pregnancy， there was no significant difference in the proportion of patients with normal creatinine and stimated glomerular filtration rate （eGFR） between the epidemic period and the non-epidemic period （86.78% vs 87.90%， χ2=0.141， P=0.708）. The patients with ALT≥5×upper limit of normal accounted for 7.94% in the epidemic period of COVID-19 and 9.54% in the non-epidemic period （χ2=0.433， P=0.511）， and the patients with severe cholestasis accounted for 7.75% in the epidemic period of COVID-19 and 9.27% in the non-epidemic period （χ2=0.392， P=0.531）. The proportion of patients with obstetric bleeding during the epidemic period of COVID-19 was significantly lower than that during the non-epidemic period （14.61% vs 24.19%， χ2=489.334， P<0.001）.  Conclusion  There is no difference in the proportion of patients with pregnancy-specific liver diseases among the patients with abnormal liver biochemical parameters in pregnancy between the epidemic period and the non-epidemic period of COVID-19， and there is no change in the proportion of patients with normal creatinine and eGFR among these patients in the epidemic period of COVID-19.

     

    • FullText(HTML)
  • loading
    • References(16)
  • [1]
    BIRKNESS-GARTMAN JE, OSHIMA K. Liver pathology in pregnancy[J]. Pathol Int, 2022, 72( 1): 1- 13. DOI: 10.1111/pin.13186.
    [2]
    BARTLETT AQ, VESCO KK, PURNELL JQ, et al. Pregnancy and weaning regulate human maternal liver size and function[J]. Proc Natl Acad Sci USA, 2021, 118( 48): e2107269118. DOI: 10.1073/pnas.2107269118.
    [3]
    MANDEL E, PECI A, CRONIN K, et al. The impact of the first, second and third waves of covid-19 on hepatitis B and C testing in Ontario, Canada[J]. J Viral Hepat, 2022, 29( 3): 205- 208. DOI: 10.1111/jvh.13637.
    [4]
    WU ZW, ZHENG XH, GUO JX, et al. Research progress on abnormal liver function in pregnancy[J]. Chin J Hepatol, 2019, 27( 8): 653- 656. DOI: 10.3760/cma.j.issn.1007-3418.2019.08.014.

    吴智威, 郑秀惠, 郭建新, 等. 妊娠期肝功能异常的研究进展[J]. 中华肝脏病杂志, 2019, 27( 8): 653- 656. DOI: 10.3760/cma.j.issn.1007-3418.2019.08.014.
    [5]
    FENG Y, LYU JQ. Investigation on the prevalence of gestational liver disease in Jiaxing area[J]. Matern Child Heath Care China, 2017, 32( 10): 2201- 2203. DOI: 10.7620/zgfybj.j.issn.1001-4411.2017.10.55.

    冯英, 吕杰强. 嘉兴地区妊娠期肝病患病现状调查[J]. 中国妇幼保健, 2017, 32( 10): 2201- 2203. DOI: 10.7620/zgfybj.j.issn.1001-4411.2017.10.55.
    [6]
    Obstetrics Subgroup, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association. Clinical management guidelines for acute fatty liver of pregnancy in China(2022)[J]. J Clin Hepatol, 2022, 38( 4): 776- 783. DOI: 10.3760/cma.j.cn112141-20210907-00499.

    中华医学会妇产科学分会产科学组. 妊娠期急性脂肪肝临床管理指南(2022)[J]. 临床肝胆病杂志, 2022, 38( 4): 776- 783. DOI: 10.3760/cma.j.cn112141-20210907-00499.
    [7]
    LI BY, YANG HX. Comparison of clinical features in antepartum and postpartum HELLP syndrome[J]. Chin J Obstet Gynecol, 2022, 57( 12): 907- 913. DOI: 10.3760/cma.j.cn112141-20220707-00444.

    李博雅, 杨慧霞. 产前与产后HELLP综合征的临床特征分析[J]. 中华妇产科杂志, 2022, 57( 12): 907- 913. DOI: 10.3760/cma.j.cn112141-20220707-00444.
    [8]
    XU CJ, HUA KQ. Practice of obstetrics& gynecology[M]. 4th ed. Beijing: People’s Medical Publishing House, 2018.

    徐丛剑, 华克勤. 实用妇产科学[M]. 4版. 北京: 人民卫生出版社, 2018.
    [9]
    ZHAO JM, ZHANG L, ZHAO PL, et al. Relationship between main clinical indexes and prognosis of patients with liver failure[J/CD]. Chin J Liver Dis Electron Version, 2019, 11( 1): 68- 71. DOI: 10.3969/j.issn.1674-7380.2019.01.013.

    赵俊梅, 张璐, 赵培利, 等. 肝功能衰竭患者主要临床指标与预后的关系[J/CD]. 中国肝脏病杂志(电子版), 2019, 11( 1): 68- 71. DOI: 10.3969/j.issn.1674-7380.2019.01.013.
    [10]
    TERRAULT NA, WILLIAMSON C. Pregnancy-associated liver diseases[J]. Gastroenterology, 2022, 163( 1): 97- 117.e1. DOI: 10.1053/j.gastro.2022.01.060.
    [11]
    JIA JD, REN H. Wang baoen hepatology[M]. 2nd ed. Beijing: Science Press, 2022.

    贾继东, 任红. 王宝恩肝脏病学[M]. 2版. 北京: 科学出版社, 2022.
    [12]
    OU MY, HU CX, LI YP. Relationship between serum oxidative stress level and pregnancy outcome in pregnant women with intrahepatic cholestasis of pregnancy[J]. J Clin Exp Med, 2023, 22( 17): 1877- 1881. DOI: 10.3969/j.issn.1671-4695.2023.17.023.

    欧曼颖, 胡春霞, 李跃萍. 妊娠期肝内胆汁淤积症孕妇血清氧化应激水平及与妊娠结局的关系[J]. 临床和实验医学杂志, 2023, 22( 17): 1877- 1881. DOI: 10.3969/j.issn.1671-4695.2023.17.023.
    [13]
    MURASE JE, HELLER MM, BUTLER DC. Safety of dermatologic medications in pregnancy and lactation: Part I. pregnancy[J]. J Am Acad Dermatol, 2014, 70( 3): 401.e1-14;quiz 415. DOI: 10.1016/j.jaad.2013.09.010.
    [14]
    BRIGGS GG, FREEMAN RK, YAFFE SJ. Drugs in pregnancy and lactation[M]. YANG HX, DUAN T. Beijing: People’s Medical Publishing House, 2008.

    BRIGGS GG, FREEMAN RK, YAFFE SJ. 妊娠期和哺乳期用药[M]. 杨慧霞, 段涛, 译. 北京: 人民卫生出版社, 2008.
    [15]
    ZHOU PZ, CHEN YY. Evaluation of commonly used drugs in pregnancy complicated with liver diseases[J/CD]. Chin J Obstet Emerg, 2014, 3( 3): 186- 189. DOI: 10.3877/cma.j.issn.2095-3259.2014.03.009.

    周鹏志, 陈雅莹. 妊娠合并肝脏疾病的常用药物评价[J/CD]. 中华产科急救电子杂志, 2014, 3( 3): 186- 189. DOI: 10.3877/cma.j.issn.2095-3259.2014.03.009.
    [16]
    MU GD, LI JY, GAO YJ, et al. Identification and analysis of the risk of liver-related adverse drug reaction in pregnant women[J]. J Clin Hepatol, 2022, 38( 8): 1834- 1838. DOI: 10.3969/j.issn.1001-5256.2022.08.021.

    母光頔, 李佳怡, 高云娟, 等. 妊娠女性药物相关肝损伤风险的识别及分析[J]. 临床肝胆病杂志, 2022, 38( 8): 1834- 1838. DOI: 10.3969/j.issn.1001-5256.2022.08.021.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(6)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (245) PDF downloads(31) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return